|

Sirolimus Clinical Trials

18 actively recruiting trials across 11 locations

Also known as: AY 22989, AY-22989, AY22989, RAPA, RAPAMYCIN +10 more

Pipeline

Phase 1: 3Phase 2: 5Phase 4: 1Phase 1/2: 7Phase 2/3: 1

Top Sponsors

  • National Cancer Institute (NCI)6
  • Fred Hutchinson Cancer Center2
  • City of Hope Medical Center2
  • University of Nebraska1
  • University of Michigan Rogel Cancer Center1

Indications

  • Cancer16
  • Hematologic Neoplasms3
  • Lung Cancer3
  • Myelodysplastic Syndrome2
  • Acute Myeloid Leukemia2

Bethesda, Maryland4 trials

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

National Institutes of Health Clinical Center

Phase 1/2
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center

Phase 1
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Duarte, California3 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

City of Hope Medical Center

Phase 1
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

City of Hope

Phase 1/2

Other2 trials

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Phase 2/3
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Phase 4

Birmingham, Alabama1 trial

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

University of Alabama at Birmingham

Phase 2

Scottsdale, Arizona1 trial

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Mayo Clinic, 13400 E. Shea Boulevard

Phase 1/2

La Jolla, California1 trial

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

UC San Diego Moores Cancer Center

Phase 1/2

Stanford, California1 trial

Safety and Durability of Sirolimus for Treatment of LAM

Stanford University Medical Center

Tampa, Florida1 trial

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Moffitt Cancer Center

Phase 2

Atlanta, Georgia1 trial

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Aflac Cancer & Blood Disorders Centers

Phase 2

Ann Arbor, Michigan1 trial

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

University of Michigan Cancer Center

Phase 2

Omaha, Nebraska1 trial

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

University of Nebraska Medical Center

Phase 2

Seattle, Washington1 trial

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.